Cancer Genetics Explained: How Tumors Hijack DNA and Scientific Breakthroughs that Fight Back

In February 2026, researchers at the Spanish National Cancer Research Centre published a finding that changed how scientists understand one of the most destructive events in tumour development. They identified the enzyme responsible for chromothripsis — a catastrophic process in which an entire chromosome is shattered into dozens or hundreds of fragments, then randomly reassembled in the wrong order. The enzyme is called N4BP2, and it is present in roughly one in four human cancers.

Chromothripsis had been known since 2011, but for fifteen years nobody knew what caused it. Now they do — and understanding the cause means understanding, for the first time, a molecular mechanism that drives roughly a quarter of all human cancer, affecting hundreds of millions of people worldwide.

Cancer is not a single disease. It is a vast collection of diseases — over 100 distinct types — united by one fundamental characteristic: cells that have lost the genetic controls regulating their growth and division, and that now multiply without limit, invade surrounding tissue, and spread to distant organs. At its core, cancer is a disease of DNA. Every case begins with a genetic error — a mutation, a deletion, an amplification, a rearrangement — that disrupts the machinery keeping cell division under precise control.

In a real sense, cancer is evolution happening inside you, at cellular speed. Understanding that machinery — how it works, how it breaks, and how it can be repaired or targeted — is advancing faster in 2026 than at any previous point in history.

What Happens to DNA When Cancer Develops

Every cell in your body divides according to a tightly regulated programme. When a cell divides, it copies its entire genome — about three billion base pairs of DNA — and gives one complete copy to each daughter cell. The process is not perfectly accurate: the human genome accumulates an average of one to two new mutations per cell division simply through the natural imprecision of DNA replication.

Most of these mutations are harmless. They fall in regions that do not affect function, or are corrected by the cell’s repair machinery before they cause damage. A small fraction, however, land in genes that regulate cell growth — and there they can tip the balance between controlled proliferation and cancer.

Researchers distinguish two broad categories of cancer-relevant genes. Oncogenes, when mutated, actively drive cell growth — like a stuck accelerator. Tumour suppressor genes normally restrain division — like a brake. Cancer typically involves both: oncogenes switched on inappropriately, and tumour suppressors inactivated. Cancer development is not random but evolutionary: mutations that give a cell a survival advantage are selected over time, building on one another across successive cell generations. A single mutation is rarely enough; most tumours require several genetic alterations, accumulated over years or decades, before a cell turns fully malignant.

The Hallmarks of Cancer, Updated for 2026

In 2000, Douglas Hanahan and Robert Weinberg published one of the most influential papers in the history of cancer biology, describing the “hallmarks of cancer” — a set of acquired capabilities that separate cancer cells from normal ones. The original list held six; it has been revised twice since, and by 2026 the framework maintained by the Jackson Laboratory recognises an expanded set of capabilities.

These include sustained growth signalling, in which cancer cells generate their own growth signals; resistance to the mechanisms that would normally suppress excessive growth; evasion of programmed cell death; and replicative immortality — achieved largely by reactivating telomerase, the enzyme that maintains telomere length, as explored in our article on telomeres and ageing. Cancer cells also stimulate the growth of new blood vessels to feed the tumour, and invade surrounding tissue to spread through the bloodstream to distant organs — the metastasis that makes cancer so lethal.

The most recent additions to the framework include epigenetic reprogramming — silencing tumour suppressor genes through epigenetic modifications rather than mutation — and phenotypic plasticity, the ability of cancer cells to switch between different states, which makes them harder to target.

Oncogenes: The Molecular Accelerators

Among the most studied oncogenes are the RAS family — KRAS, HRAS, and NRAS — which encode proteins that act as molecular switches in cell signalling, toggling between active and inactive states to control growth. When mutated, the switch jams permanently in the “on” position, driving division regardless of external signals.

KRAS mutations are among the most common cancer drivers across many tumour types, including colorectal, lung, and pancreatic cancers. For decades KRAS was considered “undruggable” — its structure offered no obvious pocket for a drug to grip. The development of KRAS G12C inhibitors in recent years broke that barrier, and 2026 research is focused on overcoming the drug resistance that eventually emerges in most treated patients. HER2 is another oncogene of major clinical importance: gene amplification, in which a stretch of DNA is duplicated many times, can cause HER2 to be massively overexpressed, driving aggressive growth. HER2-targeted therapies have transformed treatment of HER2-positive breast cancer, and testing for HER2 amplification is now routine.

Pancreatic Cancer and the GATA6 Discovery

In March 2026, scientists published a finding with major implications for one of the deadliest cancers. Pancreatic cancer kills roughly 90 percent of patients within five years of diagnosis — largely because it is usually detected late and rapidly develops resistance to available chemotherapy.

Researchers identified a gene called GATA6 as a crucial molecular switch determining whether pancreatic tumours resist chemotherapy or respond to it. GATA6 keeps tumours in a more differentiated state — closer to normal pancreatic tissue — which makes them more sensitive to treatment. When GATA6 falls silent, tumours shift into a more primitive, stem-cell-like state that is profoundly chemotherapy-resistant.

This opens a strategy not previously considered: rather than attacking cancer cells directly, drugs that restore GATA6 activity could shift resistant tumours back into a treatable state. Studies are now underway to find compounds that can do exactly that. For a cancer whose survival rates have barely improved in decades, identifying a molecular switch that controls treatment resistance is a genuinely significant step.

A Hidden Layer of Cancer: RNA and Epigenetics

In February 2026, a study revealed an entirely new dimension of cancer biology. Researchers investigating breast cancer identified a previously uncharacterised class of RNA molecules that form unique molecular signatures across dozens of tumour types — part of what they call a “hidden layer” of the cancer genome, invisible to standard DNA sequencing.

The discovery matters because it suggests cancer’s genetic complexity is even greater than current models account for. Cancer genomics has, until recently, focused mainly on DNA mutations. The emerging science of the cancer epitranscriptome — the chemical modifications carried on RNA — is revealing that cancer also hijacks RNA-level regulation, creating new therapeutic targets and new diagnostic biomarkers.

Cancer’s relationship with epigenetics is equally central, as explored in our article on epigenetics and gene expression. Cancers often carry multiple epigenetic errors that reinforce one another — keeping tumour suppressor genes permanently silenced while pro-cancer genes stay active. Crucially, unlike DNA mutations these errors are potentially reversible, and several epigenetic drugs have already received regulatory approval for specific cancers.

Chromothripsis: When Chromosomes Shatter

The February 2026 identification of N4BP2 as the enzyme behind chromothripsis is one of the most mechanistically important cancer discoveries of recent years. Chromothripsis — from the Greek for “chromosome shattering” — is a process in which a chromosome undergoes catastrophic fragmentation during cell division, producing dozens or hundreds of pieces that are then randomly stitched back together in the wrong order.

The rearrangements this produces can simultaneously inactivate multiple tumour suppressor genes and amplify multiple oncogenes in a single catastrophic event — compressing into one cell division what would otherwise take years of gradual mutation. Chromothripsis has been found in about one in four human cancers, and is especially common in aggressive tumours including certain bone cancers, glioblastoma, and small-cell lung cancer. Knowing that N4BP2 is the culprit opens a path toward targeting it — potentially heading off the chromosome-shattering that turns a pre-cancerous cell into a fully malignant one of catastrophic genomic complexity.

Precision Oncology: Treating the Mutation, Not the Organ

The most consequential shift in cancer treatment over two decades has been the move from organ-based treatment — chemotherapy designed for “breast cancer” or “lung cancer” — toward mutation-based treatment aimed at any cancer carrying a specific driver mutation, wherever it originated.

According to the American Association for Cancer Research’s 2026 forecasts, this year is being seen as one where novel chemistry meets earlier care, guided by precision models that move beyond DNA-only thinking. A particularly promising class is the “chemical inducers of proximity” — molecules that can address previously undruggable targets by forcing cancer-promoting proteins to interact with the cell’s own degradation machinery.

As explored in our article on gene editing in 2026, CRISPR-based approaches are increasingly applied to cancer — both as research tools for finding which genes cancer cells depend on, and as potential therapies targeting cancer-specific mutations with a precision conventional drugs cannot match. CAR-T cell therapy, which engineers immune cells to recognise and destroy cancer, has already produced remarkable results in blood cancers and is being pushed toward solid tumours.

Personalisation is advancing further through tumour mutational burden analysis — sequencing a tumour’s genome to identify its mutations and the drugs most likely to work. A 2026 precision oncology review notes that this lets clinicians separate driver mutations, which actively promote growth, from genetically neutral passenger mutations — focusing treatment on the changes that actually matter.

Turning the Immune System Against Cancer

Your immune system already patrols for abnormal cells and destroys many would-be cancers before they take hold. The problem is that successful tumours evolve ways to hide. One of their favourite tricks is to exploit the immune system’s own safety brakes — molecular “checkpoints” such as PD-1, PD-L1, and CTLA-4 that normally stop immune cells attacking healthy tissue. By switching these brakes on, a tumour can render itself effectively invisible.

Checkpoint-inhibitor drugs release those brakes, unleashing the patient’s own immune cells on the cancer. The discovery of this approach earned James Allison and Tasuku Honjo the 2018 Nobel Prize in Physiology or Medicine, and it has produced durable remissions in cancers, such as advanced melanoma and some lung cancers, that were once nearly untreatable. The frontier now is understanding why only a subset of patients respond — a question that turns out to depend heavily on a tumour’s genetics, its mutational burden, and the epigenetic state of both the cancer and the immune cells around it.

Reading Cancer in a Drop of Blood

Tumours constantly shed fragments of their DNA into the bloodstream. Sequencing this circulating tumour DNA from a simple blood draw — a “liquid biopsy” — is one of the most transformative ideas in modern oncology. Instead of a painful, risky tissue biopsy, a vial of blood can reveal which mutations a tumour carries, track whether a treatment is working in near real time, and catch the emergence of drug resistance months before a scan would show it.

The most ambitious extension is multi-cancer early detection: blood tests that scan for the molecular signatures of many cancers at once, aiming to catch tumours while they are still small and curable. Because survival for most cancers depends enormously on how early they are found, a reliable test of this kind would be among the most consequential advances in the history of the disease. The science is not yet perfected — false positives and missed cancers remain real challenges — but the trajectory points toward a future in which cancer is intercepted from a routine blood sample long before symptoms appear.

Cancer as a Disease of Ageing

One of the most important but underappreciated aspects of cancer biology is its intimate connection to ageing. The great majority of cancers are diseases of ageing — incidence rises steeply with age, and not simply because older people have had more time to accumulate mutations.

Ageing and cancer share fundamental mechanisms. The telomere shortening that drives cellular senescence in ageing tissue also creates genomic instability: when critically short telomeres are misread as broken DNA ends and repaired incorrectly, they can fuse chromosomes together, generating the massive rearrangements that fuel malignant transformation. The build-up of senescent cells in ageing tissue creates a pro-inflammatory environment that actively promotes tumour growth and invasion.

The epigenetic changes that accumulate with age — drift in methylation patterns, gradual reorganisation of chromatin — are strikingly similar to the disruptions found in cancer cells, and may prime cells for transformation by silencing tumour suppressor genes in the same way cancer-specific events do. Cancer and ageing are not parallel processes running side by side. At the molecular level, they are deeply intertwined.

What Scientists Say

Keith Flaherty of Massachusetts General Hospital, contributing to the AACR’s 2026 expert forecast, singled out advances in novel chemistry aimed at intercepting cancer early as the most exciting near-term prospect. The goal, he explained, is to find and target pre-malignant cells — those already carrying driver mutations but not yet fully cancerous — before a tumour establishes itself. Intercepting cancer at that stage would transform survival for many tumour types.

Researchers at the Van Andel Institute, describing their cancer-epigenetics programme in early 2026, stressed that cancer’s epigenetic errors are a promising avenue for treatment precisely because they are not permanent. Unlike DNA mutations, epigenetic silencing can potentially be reversed — and several approved epigenetic drugs already show that reversing these changes can re-sensitise tumours to other therapies. Taken together, a 2026 precision oncology review observes, cancer genomics now lets clinicians identify the driver mutations promoting a tumour’s growth, distinguish them from harmless passenger mutations, and select targeted therapies with a precision unimaginable two decades ago — the most important structural change in oncology since the advent of chemotherapy, a shift from treating tumour type to treating tumour genotype.

The Shape of What Is Coming

Put the pieces together and a picture emerges of where cancer medicine is heading. The enzyme behind chromothripsis has a name. The molecular switch governing chemotherapy resistance in pancreatic cancer has been found. A hidden RNA layer of the cancer genome is being read for the first time. The immune system can be unleashed against tumours, mutations can be matched to targeted drugs, and cancer can increasingly be detected — and one day intercepted — from a drop of blood.

None of this means cancer is solved. It remains one of the most formidable adversaries in medicine precisely because it is not a fixed target but an evolving one — a Darwinian process unfolding inside the body, endlessly generating new variation for treatment to chase. But the balance of the contest is shifting. For most of history, cancer was a black box: we saw its effects and fought its symptoms without understanding its cause. Now, for the first time, we are reading the exact molecular sabotage that turns a healthy cell malignant — and learning, gene by gene, to undo it.

There is a strange intimacy to this science. Cancer is not an invader from outside; it is your own cells, your own DNA, following the logic of evolution to a destructive end. To understand cancer is, in a sense, to understand something fundamental about what it means to be a living, dividing, mutating organism. And to learn to read that story at the level of single letters of the genome is one of the quiet triumphs of our age.

Frequently Asked Questions

Sources

• Jackson Laboratory — The Hallmarks of Cancer, 2026 Edition
• ScienceDaily — GATA6 and Pancreatic Cancer Chemoresistance (March 2026)
• ScienceDaily — A Hidden RNA Layer of Cancer (February 2026)
• ScienceDaily — Enzyme Behind Chromothripsis, N4BP2 (February 2026)
• Van Andel Institute — Cancer Research in 2026
• AACR — Experts Forecast Cancer Advances in 2026
• Wikipedia — Hallmarks of Cancer
• Wikipedia — Chromothripsis